Format

Send to

Choose Destination
Semin Cell Dev Biol. 2012 Dec;23(9):993-9. doi: 10.1016/j.semcdb.2012.09.014. Epub 2012 Oct 9.

The FDA and designing clinical trials for chronic cutaneous ulcers.

Author information

1
University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, 1321 NW 14th Street, Suite 504, Miami, FL 33134, USA.

Abstract

Treatment of chronic wounds can present a challenge, with many patients remaining refractory to available advanced therapies. As such, there is a strong need for the development of new products. Unfortunately, despite this demand, few new wound-related drugs have been approved over the past decade. This is in part due to unsuccessful clinical trials and subsequent lack of Food and Drug Administration (FDA) approval. In this article, we discuss the FDA approval process, how it relates to chronic wound trials, common issues that arise, and how best to manage them. Additionally, problems encountered specific to diabetic foot ulcers (DFU) and venous leg ulcers (VLU) are addressed. Careful construction of a clinical trial is necessary in order to achieve the best possible efficacy outcomes and thereby, gain FDA approval. How to design an optimal trial is outlined.

PMID:
23063664
DOI:
10.1016/j.semcdb.2012.09.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center